医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sumitomo Heavy Industries, Ltd. Obtains Medical Device Approval for Manufacturing and Sales of Accelerator Based BNCT System and the Dose Calculation Program in Japan

2020年03月12日 PM03:11
このエントリーをはてなブックマークに追加


 

TOKYO

Sumitomo Heavy Industries, Ltd. (TOKYO:6302)(President: Shinji Shimomura, referred as SHI hereinafter) has performed clinical trial of the BNCT*1) (Boron Neutron Capture Therapy) system using an accelerator (cyclotron), targeting carcinoma of the head and neck region in collaboration with STELLA PHARMA CORPORATION (President: Tomoyuki Asano). And SHI has applied the system for new medical device approval on 11th October, 2019. Today, we would like to announce that Sumitomo Heavy Industries, Ltd. obtains new medical device approval for manufacturing and sales of accelerator based BNCT system (NeuCureTM System) and the dose calculation program (NeuCureTM Dose Engine) from Japanese Ministry of Health, Labor and Welfare. These are the world’s first medical devices for BNCT.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200311005853/en/

Accelerator based BNCT system and its cyclotron (Graphic: Business Wire)

Accelerator based BNCT system and its cyclotron (Graphic: Business Wire)

Market and SHI’s target

BNCT is unique radiation therapy method which is led by Japanese researchers. SHI believes better treatment will be provided to patients in the world. Once STELLA PHARMA CORPORATION obtains the drug application approval, SHI would like to develop BNCT market globally together with partners by means of sending information of BNCT and the clinical outcome to the world. It may take years for obtaining global common recognition. However, SHI would like to install more than 100 systems globally as a long term target. SHI will keep making efforts to improve and develop NeuCureTM system and NeuCureTM Dose Engine.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005853/en/

CONTACT

Sumitomo Heavy Industries, Ltd.

Corporate Communication Dept.

Takuto Ono, +81-3-6737-2332

shi.zshi_koho@shi-g.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高